Injection Site Rotation and Lipohypertrophy
What lipohypertrophy is, why injection guidance insists on rotating sites, and what the FITTER recommendations say about spacing, needle reuse and inspection.
There is usually one spot that feels easiest. It is slightly less sensitive than the others, it is easy to reach, and after a few weeks it becomes the default without anyone deciding that it should.
That is precisely the mechanism by which lipohypertrophy develops.
What is lipohypertrophy?
Lipohypertrophy is a thickened, rubbery swelling of the subcutaneous tissue that forms where injections are repeatedly delivered into the same area. The tissue responds to repeated trauma by accumulating fat and fibrous tissue.
Two features make it easy to miss:
- It is usually painless, so there is no signal telling anyone to stop.
- It is often easier to feel than to see. Palpation detects areas that visual inspection does not, which is why clinical guidance describes examining sites by touch. Imaging studies using ultrasound have characterised these changes in more detail.
The affected area can also become slightly less sensitive — which makes it more comfortable to inject into, which reinforces the behaviour that caused it.
Why it matters: absorption stops being predictable
This is the part that turns a cosmetic issue into a practical one. Tissue that has been remodelled does not absorb the same way healthy tissue does. Uptake becomes slower, less complete, and — most importantly — more variable from one occasion to the next.
The worldwide injection technique survey, published alongside the FITTER recommendations in 2016, quantified the consequences in insulin users:
| Finding | Result reported |
|---|---|
| Prevalence | Roughly one in three participants appeared to have lipohypertrophy |
| Insulin requirement | About 10 more units per day in the affected group |
| Glycaemic control | HbA1c approximately 0.5 percentage points higher |
The same survey found that a substantial share of respondents had injected into the same small area repeatedly, sometimes for days at a time.
What the recommendations say
The FITTER guidance is specific, and it is specific because vagueness is what produces the problem:
- Rotate between zones and within them. Moving between abdomen, thigh, buttock and upper arm is not enough on its own if every injection into the abdomen lands in the same square centimetre.
- Use a structured scheme. Divide a site into quadrants — or halves for thigh and buttock — use one per week, and move in a consistent direction so the sequence is never ambiguous.
- Keep at least one centimetre from the previous injection, roughly an adult finger’s width.
- Do not reuse needles. Needle reuse is among the practices associated with lipohypertrophy in the survey data.
- Inspect and palpate sites, and avoid injecting into an area that is already affected.
This evidence base comes from insulin therapy, where the volume of research is largest and the consequences are most measurable. The tissue mechanism is a response to repeated injection rather than to insulin specifically, but any product’s own guidance, and the advice of a treating clinician, is the authority for that product.
How quickly a scheme like this comes back round to the same quadrant is not set by the scheme — it is set by injection frequency, which follows from the compound’s half-life. A weekly injection gives any one site four weeks to recover; a daily one gives it a fraction of that, and needs a correspondingly finer rotation.
Everything above concerns what happens at the skin. What happens before that — handling before injecting, and whether the vial has been kept cold, dark and undisturbed — is a separate failure mode with its own rules, and it degrades the dose rather than the site.
Why this is a record-keeping problem
Rotation is a scheme that only works if you know where the last one went. Over a protocol lasting months, that is dozens of data points nobody remembers accurately — and the failure mode is silent, because the consequence is a gradually widening variance in absorption rather than an event.
This is one of the few things software is genuinely better at than a person, and for an unusually plain reason: it is not a judgement call, it is a lookup. Where did the last four go, and which quadrant is therefore due. A person answers that badly after a month; a list answers it correctly forever.
PeptCycle records the site with every logged dose and offers the next one in the scheme when the reminder fires, so the rotation is something you follow rather than something you have to reconstruct.
Frequently asked questions
What is lipohypertrophy?
A thickened, rubbery swelling of subcutaneous tissue that develops where injections are repeatedly given in the same place. It is often firm and painless, and small areas can be easier to feel by palpation than to see.
Why does it matter if absorption is affected?
Because absorption from affected tissue becomes slower and less predictable. In the worldwide injection technique survey, participants with lipohypertrophy used roughly 10 more units of insulin per day and had HbA1c about 0.5 percentage points higher than those without it.
How far apart should injections be?
The FITTER recommendations describe dividing a site into quadrants or halves, using one per week and moving in a consistent direction, and keeping each injection at least one centimetre from the previous one. Those recommendations were written for insulin therapy.
Does needle reuse contribute?
Reusing needles is one of the practices associated with lipohypertrophy in the survey data, along with failing to rotate and injecting into a small area repeatedly. Single use is the standard recommendation.
Sources
- Frid A. et al., New Insulin Delivery Recommendations (FITTER), Mayo Clinic Proceedings 2016
- Frid A. et al., Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional, Mayo Clinic Proceedings 2016
- Yang H. et al., Ultrasound Characteristics and Prognostic Features of Insulin-Induced Lipohypertrophy: A Systematic Review, 2025